Real-life GH dosing patterns in children with GHD, TS or born SGA: a report from the NordiNet (R) International Outcome Study
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10373787" target="_blank" >RIV/00216208:11130/17:10373787 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/17:10373787
Result on the web
<a href="https://doi.org/10.1530/EJE-16-1055" target="_blank" >https://doi.org/10.1530/EJE-16-1055</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1530/EJE-16-1055" target="_blank" >10.1530/EJE-16-1055</a>
Alternative languages
Result language
angličtina
Original language name
Real-life GH dosing patterns in children with GHD, TS or born SGA: a report from the NordiNet (R) International Outcome Study
Original language description
Objective: To describe real-life dosing patterns in children with growth hormone deficiency (GHD), born small for gestational age (SGA) or with Turner syndrome (TS) receiving growth hormone (GH) and enrolled in the NordiNet International Outcome Study (IOS; NCT00960128) between 2006 and 2016. Design: This non-interventional, multicentre study included paediatric patients diagnosed with GHD (isolated (IGHD) or multiple pituitary hormone deficiency (MPHD)), born SGA or with TS and treated according to everyday clinical practice from the Czech Republic (IGHD/MPHD/SGA/TS: n = 425/61/316/119), France (n = 1404/188/970/206), Germany (n = 2603/351/1387/411) and the UK (n = 259/60/87/35). Methods: GH dosing was compared descriptively across countries and indications. Proportions of patients by GH dose group (low/medium/high) or GH dose change (decrease/increase/no change) during years 1 and 2 were also evaluated across countries and indications. Results: In the Czech Republic, GH dosing was generally within recommended levels. In France, average GH doses were higher for patients with IGHD, MPHD and SGA than in other countries. GH doses in TS tended to be at the lower end of the recommended label range, especially in Germany and the UK; the majority of patients were in the low-dose group. A significant inverse association between baseline height standard deviation score and GH dose was shown (P < 0.05); shorter patients received higher doses. Changes in GH dose, particularly increases, were more common in the second (40%) than in the first year (25%). Conclusions: GH dosing varies considerably across countries and indications. In particular, almost half of girls with TS received GH doses below practice guidelines and label recommendations.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30202 - Endocrinology and metabolism (including diabetes, hormones)
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Endocrinology
ISSN
0804-4643
e-ISSN
—
Volume of the periodical
177
Issue of the periodical within the volume
2
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
145-155
UT code for WoS article
000406480700010
EID of the result in the Scopus database
2-s2.0-85023209241